J Korean Soc Radiol.  2023 Jan;84(1):51-74. 10.3348/jksr.2022.0154.

Clinical Application and Limitations of Myeloma Response Assessment and Diagnosis System (MY-RADS)

• Kim DK
• Park SS
• Jung JY

• KMID: 2539302
• DOI: http://doi.org/10.3348/jksr.2022.0154

Abstract

Multiple myeloma, which is a proliferative disease of plasma cells that originate from a single clone, is the second most common hematologic malignancy following non-Hodgkin lymphoma. In the past, its diagnosis was made based on clinical findings (so-called “CRAB”) and a skeletal survey using radiographs. However, since the implementation of the International Myeloma Working Group’s revised guideline regarding the radiologic diagnosis of multiple myeloma, whole-body (WB) MRI has emerged to play a central role in the early diagnosis of multiple myeloma. Diffusion-weighted imaging and fat quantification using Dixon methods enable treatment response assessment by MRI. In keeping with the trend, a multi-institutional and multidisciplinary consensus for standardized image acquisition and reporting known as the Myeloma Response Assessment and Diagnostic System (MY-RADS) has recently been proposed. This review aims to describe the clinical application of WB-MRI based on MYRADS in multiple myeloma, discuss its limitations, and suggest future directions for improvement.

Keyword

Multiple Myeloma; Whole Body Imaging; Magnetic Resonance Imaging; Myeloma Response Assessment and Diagnosis System